Date updated:05-17-2007
Okay, so I got hit bad by Dendreon, but who didn't? It was worth it to take a chance, especially after the surprisingly positive AC recommendation. But hindsight is 20/20, and I was blinded by message board contributors who didn't see the writing on the wall that pointed towards an approvable letter. But all is not lost if you are a true DNDN long as I still believe that the therapy has potential, and the experience has opened me up to the emerging cancer field, which even has it's own index fund in HHJ. This portfolio keeps track of all the stocks in this field, hopefully separating the wheat from the chaff.

-
ADLR
Adolor Corporatio - $1.47
- -2.00%
- $1.47
No Analysis added

-
AEZS
Aeterna Zentaris - $1.04
- -4.59%
- $1.12
Adam Feuerstein answers questions about Genitope, Immunogen, and Nymox in his Biotech-Stock mailbag (http://www.thestreet.com/_tscs/newsanalysis/biotech/10354735.html). This is the only reason I added these stocks to this portfolio. Mainly to track to see if he is right. A reader asked if Genitope is the next Dendreon. Feuerstein thinks not, but sees competition with Genetech's non-Hodgkin's lymphoma drug. He doesn't see much hope for Immunogen either. And he doesn't like Nymox, instead recommending Spectrum and Aeterna Zentaris. So these stocks go into the Favorite column, and the others into Least Favorite. We'll see where they are in 6 months.

-
AGEN
Antigenics Inc. - $1.02
- +5.26%
- $0.9802
No Analysis added

-
ARRY
Array Biopharma I - $2.00
- -0.99%
- $2.10
No Analysis added

-
BDSI
Biodelivery Scien - $4.13
- -0.96%
- $4.15
No Analysis added

-
BUF
N/a - $0.19
- 0.00
- $0.19
No Analysis added

-
CEGE
Cege - $0.00
- N/A
- $N/A
Mentioned on the yahoo message boards. People noticed how it tracked DNDN back when that stock was running. Need more info, though.

-
CYTR
Cytrx Corporation - $0.9499
- +5.54%
- $0.91
No Analysis added
- Top Professional Portfolios
- 1. Navellier & Associ...
- 2. Fidelity Contrafund - ...
- 3. Argus Management
- 4. WisdomTree Intl Consum...
- 5. Charlie Munger
- show all
- Top Do-It-Yourself Portfolios
- » John Shier
- » Joy
- » tsamanuli Portfolio 1
- » brueckenc Portfolio 1
- » Fundsonly Portfolio 1
- show all
- Most Viewed Portfolios
- » Warren Buffett
- » George Soros
- » T. Boone Pickens - BP Cap...
- » Carl Icahn
- » Renaissance Technologies
- show all
By Roberto Pedone Posted on Nov. 6, 2009 According to Jim Cramer, the bears are tellinginvestors six lies. On Wednesday’s “Mad Money” TV show, Cramer said if you ...
By Roberto Pedone Posted on Nov. 5, 2009 The traders on CNBC’s “Fast Money” told their viewers what they must know after Warren Buffett announced on Tuesday his l...
By Jonas Elmerraji Posted on Nov. 4, 2009 For investors who seek out short-squeeze opportunities, there’s no time as important as earnings season. Earnings are one of...
By Stockpickr Staff Posted on Nov. 4, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is...
A. i bought into ECLP last thursday. . They
compete with CERNER on putting in big
medical records systems into hospitals.
I believe the industry is going to
consolidate as well.
A. The only one I own : SLX,
too hard pick a winner out all of them
Here is the stock list of some of the largest % losers from Nov. 2, 2009. more
These are some of the stocks mentioned on TheStreet.com TV on Sept. 2. Click the URL below each stock to watch the videos. more
Here is a list of some of the biggest stocks that hit 52-week lows on Nov. 2, 2009. more













Comments not available